Olanzapine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Olanzapine: From Schizophrenia to Neurotic Depression
One-Sentence Summary
Olanzapine is a second-generation (atypical) antipsychotic, established for the treatment of schizophrenia and bipolar I disorder. Among 10 TxGNN-predicted indications in this evidence pack, the model’s raw top-ranked hit (“benign paroxysmal torticollis of infancy”) has zero supporting evidence and is flagged by the pack itself as likely knowledge-graph noise. The strongest evidence-backed candidate is Neurotic Depression (an ICD-9 legacy term overlapping with treatment-resistant/dysthymic depression), supported by 0 dedicated clinical trials but 25 relevant publications, including systematic reviews/network meta-analyses and the pivotal trial behind the already-approved olanzapine-fluoxetine combination (Symbyax).
Note on candidate selection: This evidence pack scores 10 predicted indications by raw TxGNN similarity, not by evidence quality. Five candidates (benign paroxysmal torticollis of infancy, distal 17p13.3 microdeletion syndrome, retinal dystrophy with extraocular anomalies, Ohdo syndrome, childhood apraxia of speech) are rated L5/Hold — no clinical or mechanistic link, likely embedding artifacts. This report focuses on Neurotic Depression (rank 6), the highest evidence-tier candidate (L2, “Proceed with Guardrails”), tied closely with “melancholia” (rank 7, same evidence base).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia / Bipolar I Disorder (general pharmacological knowledge — not present in this evidence pack; EU regulatory record shows Not marketed / 0 authorizations) |
| Predicted New Indication | Neurotic Depression |
| TxGNN Prediction Score | 98.77% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this evidence pack (data gap DG002). Based on general pharmacological knowledge, Olanzapine is an atypical antipsychotic acting primarily through 5-HT2A and D2 receptor antagonism, with additional activity at histaminergic, muscarinic, and adrenergic receptors. Its efficacy in schizophrenia and bipolar I disorder is well established.
“Neurotic depression” is a legacy ICD-9 diagnostic term that largely maps onto what is now classified as dysthymia or mild-to-moderate/treatment-resistant major depressive disorder (MDD). The mechanistic rationale for olanzapine in this space is not speculative: the olanzapine-fluoxetine combination (OFC, marketed as Symbyax) is already an approved therapy for treatment-resistant depression and bipolar depression, based on the premise that 5-HT2A antagonism augments SSRI-driven monoaminergic antidepressant effects. The literature base for this candidate consists largely of systematic reviews and network meta-analyses of antipsychotic augmentation in treatment-resistant depression, rather than trials targeting “neurotic depression” by name — this terminology gap is the main caveat requiring clarification before further action.
Compared to the raw top-scoring TxGNN prediction (benign paroxysmal torticollis of infancy, a pediatric migraine-variant/vestibular condition with no plausible D2/5-HT2A link and zero literature support), Neurotic Depression represents a mechanistically coherent, evidence-anchored candidate consistent with olanzapine’s known psychiatric pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14609883 | 2003 | RCT | Archives of General Psychiatry | Pivotal trial establishing efficacy of olanzapine and olanzapine-fluoxetine combination (OFC) in bipolar I depression — basis for OFC’s regulatory approval |
| 19640209 | 2009 | Review | Expert Opinion on Pharmacotherapy | Reviews efficacy/safety data of fluoxetine-olanzapine combination in treatment-resistant major depression |
| 17845277 | 2007 | RCT (post-hoc) | Bipolar Disorders | Analyzes onset of antidepressant effect for OFC vs. olanzapine alone in bipolar depression |
| 34986373 | 2022 | Systematic Review + NMA | Journal of Affective Disorders | Compares augmentation agents (incl. olanzapine) for treatment-resistant depression |
| 38360024 | 2024 | Systematic Review + NMA | The Lancet Psychiatry | Assesses efficacy/safety of pharmacological treatments for psychotic depression |
| 35861202 | 2023 | Systematic Review + Meta-analysis | Journal of Psychopharmacology | Evaluates augmentation/combination treatments for early-stage treatment-resistant depression |
| 38487836 | 2024 | Systematic Review + NMA | European Psychiatry | Bayesian NMA of FDA-approved atypical antipsychotics (incl. olanzapine) for bipolar depression |
| 37149344 | 2023 | Review | The Psychiatric Clinics of North America | Reviews antidepressant/atypical antipsychotic pharmacotherapy for treatment-resistant depression |
| 36855876 | 2023 | Review | American Journal of Psychiatry | Discusses role of antipsychotics in the evolving treatment-resistant depression landscape |
| 35993319 | 2022 | Systematic Review + NMA | Psychological Medicine | Efficacy/acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation |
EU Market Information
Currently no marketing authorization on file in this evidence pack (EU market status: Not marketed, 0 authorizations recorded).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple systematic reviews and network meta-analyses support atypical antipsychotic (including olanzapine) augmentation in treatment-resistant depression, and the olanzapine-fluoxetine combination is already an approved therapy for a mechanistically related indication (treatment-resistant bipolar depression). However, no trial targets “neurotic depression” specifically, and this legacy diagnostic label requires mapping to a current nosological category before clinical development can proceed.
To proceed, the following is needed:
- TFDA/EU SmPC warnings, contraindications, and drug-interaction data (currently blocking — DG001)
- Confirmed original MOA and indication documentation for olanzapine (DG002)
- Clarification of “neurotic depression” mapping to current DSM-5/ICD-11 categories (dysthymia vs. treatment-resistant MDD) to define target population
- Consider a dedicated trial or well-defined subgroup analysis rather than relying solely on indirect TRD/bipolar depression evidence
- Screen out low-evidence candidates in this pack (benign paroxysmal torticollis of infancy, distal 17p13.3 microdeletion syndrome, retinal dystrophy with extraocular anomalies, Ohdo syndrome, childhood apraxia of speech) — all L5/Hold with no clinical or mechanistic support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.